-
Sort By
-
Newest
-
Newest
-
Oldest
Executive summary Societies and governments around the world are looking at a COVID-19 vaccine as the panacea that will enable the world to recover, reconnect and regain our way of life. Since the genetic code for COVID-19 was unlocked, researchers have set out in an unprecedented and coordinated effort to make a vaccine available on…
Here’s the fourth instalment of our series on the fascinating ASX cohort of medical device developers. ImpediMed (IPD, 8.1 cents)Market capitalisation: $83.8 millionThree-year total return: -52.7% a yearAnalysts’ consensus target price: 14 cents (Thomson Reuters) You would not know it from the share price performance over the last few years, but Brisbane-based ImpediMed has put…